Antibody Created in Lab Treats MS in Mice by Preventing Immune Cells from Piercing Blood-Brain Barrier
Building on work began in stroke studies and applying it to multiple sclerosis, researchers in France report that an antibody…
Articles by Patricia Silva, PhD
Low-Quality Generic MS Drugs Can Be Both Toxic and Ineffective, Study Reports
Low-quality unauthorized generic versions of approved multiple sclerosis (MS) drugs can expose patients to danger, both through their toxic properties…
Merck KGaA’s Investigational MS Therapy Cladribine Gets EMA Marketing Authorization Application Review
Merck KGaA, Darmstadt, Germany recently announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application…
MS Rehabilitation Specialist, Susan Bennett, Receives Lifetime Achievement Award from CMSC
The Consortium of Multiple Sclerosis Centers (CMSC) has awarded Susan E. Bennett one of its highest honors, the Lifetime…
127 Progressive MS Patients Finish Treatment in Phase 2 Study of Ibudilast, MediciNova Reports
MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trial (SPRINT-MS) exploring MN-166…
127 Progressive MS Patients Finish Treatment in Phase 2 Study of Ibudilast, MediciNova Reports
MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trial (SPRINT-MS) exploring MN-166…
Access to MS Therapy in US Often Determined by Patients’ Insurance Coverage
Individual health insurance coverage largely determines a multiple sclerosis (MS) patient’s access to disease modifying drugs in the United States, mainly because…
Endece Granted New U.S. Patent for NDC-1308, Therapy to Induce Remyelination in MS
Endece was recently issued an additional U.S. patent for its lead investigational product, NDC-1308, being developed to induce remyelination…
High Depression Rates in MS Patients Tied to Brain Inflammation in Recent Study
Inflammation in a brain region called the hippocampus might explain why patients with multiple sclerosis (MS) suffer from depression far…
Workings of Common Statin, Simvastatin, Explored in Ways Relevant to Multiple Sclerosis
One of the world’s most commonly used medications — the cholesterol-lowering drug simvastatin — was found to affect the immune…
MS Patients’ Personal Circumstances Largely Shape Their Views on Therapy Preferences
Opinions voiced by multiple sclerosis (MS) patients as to what they most want from, and like in, an MS treatment…
MS Takes a Toll on Caregivers, Too, Especially on Their Mental Health
Caregivers of people with multiple sclerosis (MS) are often burdened by fatigue and depression, even anger, all of which can unwittingly reduce the quality…
Coherus’ Oral Therapy for Relapsing MS Seen to Reduce Brain Lesions by Half in Phase 2b Trial
Coherus BioSciences recently reported that its candidate therapy for multiple sclerosis (MS), CHS-131, reduced the development rate of new brain lesions…
High Blood Pressure in MS Seen to Increase Risk of Disability Progression
High blood pressure may be linked to greater overall disability in people with multiple sclerosis (MS), although the rate at which disability…
Local MS Society to Honor Colorado State University at 2016 Dinner of Champions
The president of Colorado State University (CSU), Tony Frank, will be accepting the Norman Cohn Hope Award on behalf of…
MS Progression May Be Tied to Workings of Immune Complement System in Brain Lesions
The complement system, a part of our non-adaptable (innate) immune defenses, is activated in lesions inside the brain’s gray matter and…
Micro-RNA Levels May Be Diagnostic Marker, Distinguishing MS from Other Neurological Diseases
Patients with multiple sclerosis (MS) have higher levels of a micro-RNA called miR-150 in their cerebrospinal fluid, a liquid surrounding…
4 New ‘Risk Genes’ for Multiple Sclerosis, All Controlling Other Genes, Identified in German Study
In the largest genetic study ever performed in a single country, scientists in Germany discovered four new risk genes for…
NYAS Conference on MS to Explore Emerging Diagnostics and Treatment Options
An upcoming conference will explore new and emerging treatment options for multiple sclerosis (MS), focusing on the intersection between laboratory…
Poor Physical and Cognitive Skills in MS Patients Linked to Cerebral Microbleeds
As we age, the risk that small blood vessels will start leaking into brain tissue increases, raising our risk of dementia, stroke,…
GeneFo Partners with MitoQ to Offer Energy Supplement at Discount to MS Community
GeneFo, a social-medical community that connects patients with multiple sclerosis (MS) and offers free in-house medical consulting, recently announced…
National MS Society Using Record $3M Gift to Expand Services and Outreach Programs
The National Multiple Sclerosis Society announced that it has received the largest gift ever given the organization by an individual —…
Clinical Pilates Seen to Improve Both Cognition and Muscle Strength in MS Patients
Clinical pilates can improve cognitive skills and life quality in multiple sclerosis (MS) patients, in addition to helping them physically. But the study, comparing…
Phase 2 Study to Evaluate an Oral Drug to Treat MS-related Spasticity and Cramps
Flex Pharma, Inc., announced the start of a Phase 2 clinical trial assessing the safety and efficacy of FLX-787 in multiple…
Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties
Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an…
Myelin-Producing Brain Cells Seen for 1st Time to Be Highly Diverse and Specialized
Oligodendrocytes — brain cells that wrap themselves around neurons to produce myelin — are much more diverse than previously believed.
New Zealand Clinical Trial to Test Potential of Antipsychotics to Treat SPMS
An immunologist at Victoria University of Wellington is leading a clinical trial that will use existing drugs in a new way…
Merck Joins with HAPPYneuron to Add Cognitive Training Games to MSdialog
Merck Biopharma  announced it has entered into a partnership with a French subsidiary called HAPPYneuron, and now has an exclusive license to that…
Aggressive Stem Cell Transplant Approach Halts MS for Years, But Risks are High
Autologous haematopoietic stem cell transplantation (aHSCT) has been used to stop autoimmune processes in multiple sclerosis (MS), although the treatment is…
Genmab to Begin Phase 3 Trials of Ofatumumab to Treat Relapsing Multiple Sclerosis
Genmab announced plans to soon begin a Phase 3 clinical trial program assessing the subcutaneous formulation of ofatumumab as a potential…